Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Altrazeal® exSALT™

An antimicrobial wound dressing combining a proprietary silver coating technology and nanoparticle-based powder dressing that is intended to accelerate the healing of infected wounds. 

Lipshitz Macular Implant (LMI)

An intraocular implant with two mirrors in telescopic configuration that provides visual magnification without disturbing peripheral vision to patients with age-related macular degeneration.

Tovaxin®

An autologous T-cell vaccine for the early treatment of patients with relapsing remitting multiple sclerosis.

Brilinta™ (Ticagrelor)

An oral antiplatelet agent to reduce the rate of thrombotic events in patients with acute coronary syndrome.